Online inquiry

IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ155MR)

This product GTTS-WQ155MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ155MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ407MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ14523MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ3620MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ558MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 4D5-8
GTTS-WQ12995MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ6963MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ8954MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ11672MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MHAA4549A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW